BPC-157
Read the full narrative Deep Dive on BPC-157 →
A synthetic pentadecapeptide (15 amino acids) based on a partial sequence identified in human gastric juice.
Extensively investigated since the early 1990s — primarily by Sikiric and colleagues at the University of Zagreb — for roles in tissue protection and repair, particularly tendon, ligament, muscle, and gastrointestinal healing.
Large, active preclinical literature (over 500 published articles identified by a 2025 systematic review). Human clinical research remains minimal and incomplete.
Proposed mechanism of action
Proposed / hypothesised
Preclinical studies propose effects on angiogenesis (new blood vessel formation), nitric oxide signalling pathways, and growth hormone receptor expression in tendon fibroblasts, contributing to a general cytoprotective and pro-healing effect across multiple tissue types.
What's actually established
No mechanism has been confirmed in human physiology. Everything in the left column comes from cell-culture and animal-model work — genuine, published findings, but not yet validated as the operating mechanism in people.
What's actually been published, by evidence level
Laboratory / In-vitro
Cell-culture studies examining effects on fibroblast activity and related cellular signalling.
Animal / Preclinical
Extensive rodent-model literature spanning tendon, ligament, muscle, bone, and gastrointestinal healing, dating to the early 1990s.
Early Human Evidence
A 2025 systematic review identified exactly one clinical study: a retrospective assessment of intra-articular BPC-157 injection for knee pain.
Controlled Human Evidence
A registered 2015 Phase I safety/pharmacokinetics trial (42 healthy volunteers) never posted results. A new Phase II trial for hamstring strain began recruiting in 2026 — no results yet.
Established Clinical Evidence
None identified in published, peer-reviewed form for any indication.
- Study type
- Systematic review (literature search through June 2024, PubMed/Cochrane/Embase)
- Scope
- 544 articles identified (1993–2024); only 1 clinical (human) study found
- Main finding
- Strong preclinical signal for musculoskeletal repair; the review authors report no clinical safety data were identified
- Study type
- Randomized, placebo-controlled, Phase I
- Population
- 42 healthy volunteers, oral dosing
- Status
- Last known status "active, not recruiting" (2015); overall status marked Unknown. No results have been posted.
- Study type
- Randomized, double-blind, placebo-controlled, Phase II
- Population
- Adults with acute grade II hamstring strain confirmed by MRI; subcutaneous dosing, 14 days
- Primary endpoints
- Time to return to unrestricted sport; MRI-assessed injury volume at Day 14
- Status
- Currently recruiting as of this writing — no results yet
A Phase II trial for ulcerative colitis under these compound codes is widely referenced as having shown safety and efficacy. We could not locate a published, peer-reviewed clinical trial report or an accessible primary trial record confirming these specific results.
[VERIFICATION REQUIRED]This label means the published evidence consists of laboratory and animal studies, with only minimal, incomplete human research. It is not a statement that BPC-157 does or doesn't work in people — it's a statement about how far the published research has actually progressed.
What This Evidence Does NOT Establish
- The extensive animal literature does not establish that BPC-157 produces the same effects in humans — rodent and human physiology, dosing, and metabolism differ meaningfully.
- A plausible, well-studied cellular mechanism does not prove a real-world clinical outcome in people.
- One retrospective human study (intra-articular, knee pain) is a single, small, uncontrolled data point — not confirmation of an effect.
- A registered clinical trial existing does not mean it produced a positive result — the 2015 Phase I trial never reported results at all.
- The absence of robust human trial data is not evidence that BPC-157 doesn't work — it means that research hasn't been done or hasn't been published yet.
Where the Evidence Conflicts
The 2025 systematic review's own authors note the gap directly: despite hundreds of published preclinical articles, no clinical safety data were identified. That's not two studies disagreeing — it's a field with a large animal literature and essentially no human safety or efficacy data to weigh it against. Claims that treat the animal findings as if they already answer the human question are not supported by what's actually been published.
"BPC-157 has been proven in clinical trials to heal tendons and the gut."
A large, genuine preclinical (animal and cell-culture) literature supporting tissue-repair mechanisms. One small retrospective human study on intra-articular injection for knee pain. Two registered human trials, neither with reported results yet.
BPC-157 has a substantial and consistent animal research base worth continued study. It has not been demonstrated in peer-reviewed, controlled human trials to heal tendons or gut tissue in people.
Whether the mechanisms seen in animal models produce a comparable effect in humans, at what dose, by what route, with what safety profile, and in which conditions — all of this awaits the controlled human trials that haven't been completed yet.